Clinical trials of the Northgate SD-3 dual-purpose lithotriptor for renal calculi

S. K. Swanson, T. R. Larson, F. P. Begun, D. L. Lamm, E. F. Fuchs, J. Hyman, J. L. Huffman

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The Northgate SD-3 is a bathless, portable shock wave lithotriptor made in the United States. It uses ultrasound localization and spark-gap, electrode- generated shock waves to fragment calculi in the upper urinary tract. Since October 1987, 312 treatments have been performed on 281 patients (286 kidneys) with stone burdens less than 2 cm. during clinical trials at 6 investigational sites in the United States. A fragmentation rate of 94% was achieved. Of the treatments 78% were judged successful (stone-free or fragments of less than 5 mm. remaining in an asymptomatic patient) and a 3- month stone-free rate of 58% was noted. The retreatment rate was 9% and the ancillary procedure rate was 5%. The complications (hematuria, ecchymosis, pain, obstruction) were mild and not unlike those seen in patients undergoing lithotripsy with other devices.

Original languageEnglish (US)
Pages (from-to)1047-1051
Number of pages5
JournalJournal of Urology
Issue number3 II
StatePublished - 1992
Externally publishedYes


  • clinical trials
  • kidney calculi
  • lithotripsy

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Clinical trials of the Northgate SD-3 dual-purpose lithotriptor for renal calculi'. Together they form a unique fingerprint.

Cite this